Literature DB >> 3106569

Resection of heterotopic ossification and Didronel therapy--regaining wheelchair independence in the spinal cord injured patient.

J V Subbarao, B A Nemchausky, M Gratzer.   

Abstract

Ankylosis of the joints secondary to heterotopic ossification in the spinal cord injured is not uncommon. Five patients had ankylosis of the hip and knee joints which limited their ability to function in their wheelchairs. They underwent eight resections to improve their functional capabilities. All patients were treated pre- and postoperatively with disodium etidronate (EHDP, DIDRONEL). The average interval from injury to surgery was nine years nine months and the average interval from surgery to follow-up was two years three months. With clearly defined goals, proper patient selection, good pre- and postoperative management and intense rehabilitation combined with Didronel, optimum functional results were achieved.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106569     DOI: 10.1080/01952307.1987.11719626

Source DB:  PubMed          Journal:  J Am Paraplegia Soc        ISSN: 0195-2307


  3 in total

Review 1.  A comparison of heterotopic ossification treatment within the traumatic brain and spinal cord injured population: An evidence based systematic review.

Authors:  Jo-Anne L Aubut; Swati Mehta; Nora Cullen; Robert W Teasell
Journal:  NeuroRehabilitation       Date:  2011       Impact factor: 2.138

Review 2.  A systematic review of the therapeutic interventions for heterotopic ossification after spinal cord injury.

Authors:  R W Teasell; S Mehta; J L Aubut; M C Ashe; K Sequeira; S Macaluso; L Tu
Journal:  Spinal Cord       Date:  2010-01-05       Impact factor: 2.772

3.  Association between alendronate, serum alkaline phosphatase level, and heterotopic ossification in individuals with spinal cord injury.

Authors:  Avraam Ploumis; Jayne M Donovan; Mobolaji O Olurinde; Dana M Clark; Jason C Wu; Douglas J Sohn; Kevin C O'Connor
Journal:  J Spinal Cord Med       Date:  2014-05-13       Impact factor: 1.985

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.